Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.61 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.46 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.46 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | LPAR6 | P43657 | 2/20 | 0.42 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.42 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.42 |
| ▸ | TLR2 | O60603 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11197694 | 1.00 | DNM1 (0.61) | DNM1LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL31628520 | 1.00 | DNM1 (0.61) | DNM1LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL8345191 | 1.00 | DNM1 (0.61) | DNM1LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL11181251 | 1.00 | DNM1 (0.61) | DNM1LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL11181978 | 1.00 | DNM1 (0.61) | DNM1LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL11187145 | 1.00 | DNM1 (0.61) | DNM1LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL18051492 | 1.00 | DNM1 (0.61) | DNM1LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL11189857 | 1.00 | DNM1 (0.61) | DNM1LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL17263911 | 1.00 | DNM1 (0.61) | DNM1LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL28294097 | 1.00 | DNM1 (0.61) | DNM1LPAR1LPAR3LPAR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2007-02-22 | — | — | US | disclosed |
| US-6165500-A | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2000-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | FABP4, NPC1L1, LIPA | DNM1 268/4885LPAR1 1387/4885LPAR3 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.